Article
Study on the persistence of Zika virus (ZIKV) in body fluids of patients with ZIKV infection in Brazil
Registro en:
CALVET, Guilherme Amaral et al. Study on the persistence of Zika virus (ZIKV) in body fluids of patients with ZIKV infection in Brazil. BMC Infectious Diseases, v. 18, p. 1-17, 2018.
1471-2334
10.1186/s12879-018-2965-4
Autor
Calvet, Guilherme Amaral
Kara, Edna Oliveira
Giozza, Silvana Pereira
Menezes, Camila Helena Aguiar Bôtto
Gaillard, Philippe
Franca, Rafael Freitas de Oliveira
Lacerda, Marcus Vinicius Guimarães de
Castilho, Marcia da Costa
Brasil, Patrícia
Sequeira, Patrícia Carvalho de
Mello, Maeve Brito de
Bermudez, Ximena Pamela Diaz
Modjarrad, Kayvon
Meurant, Robyn
Landoulsi, Sihem
Benzaken, Adele Schwartz
Filippis, Ana Maria Bispo de
Broutet, Nathalie Jeanne Nicole
Resumen
Background: Zika virus (ZIKV) has been identified in several body fluids of infected individuals. In most cases, it remained detected in blood from few days to 1 week after the onset of symptoms, and can persist longer in urine and in semen. ZIKV infection can have dramatic consequences such as microcephaly and Guillain-Barré syndrome. ZIKV sexual transmission has been documented. A better understanding of ZIKV presence and persistence across biologic compartments is needed to devise rational measures to prevent its transmission. Methods: This observational cohort study will recruit non-pregnant participants aged 18 years and above with
confirmed ZIKV infection [positive reverse transcriptase-polymerase chain reaction (RT-PCR) test in blood and/or urine]: symptomatic men and women in ZIKV infection acute phase, and their symptomatic or asymptomatic household/sexual infected contacts. Specimens of blood, urine, semen, vaginal secretion/menstrual blood, rectal swab, oral fluids, tears, sweat, urine and breast milk (if applicable) will be collected at pre-established intervals and tested for ZIKV RNA presence by RT-PCR, other co-infection (dengue, Chikungunya, HIV, hepatitis B and C, syphilis), antibody response (including immunoglobulins M and G), plaque reduction neutralization test (if simultaneously positive for ZIKV and dengue), and ZIKV culture and RNA sequencing. Data on socio-demographic characteristics and comorbidities will be collected in parallel. Participants will be followed up for 12 months. Discussion: This prolonged longitudinal follow-up of ZIKV infected persons with regular biologic testing and data
collection will offer a unique opportunity to investigate the presence and persistence of ZIKV in various biologic compartments, their clinical and immunological correlates as well as the possibility of ZIKV reactivation/reinfection over time. This valuable information will substantially contribute to the body of knowledge on ZIKV infection and
serve as a base for the development of more effective recommendation on the prevention of ZIKV transmission.